Literature DB >> 24736188

Effects of age and macrophage lineage on intracellular survival and cytokine induction after infection with Rhodococcus equi.

Londa J Berghaus1, Steeve Giguère2, Tracy L Sturgill1.   

Abstract

Rhodococcus equi, a facultative intracellular pathogen of macrophages, causes life-threatening pneumonia in foals and in people with underlying immune deficiencies. As a basis for this study, we hypothesized that macrophage lineage and age would affect intracellular survival of R. equi and cytokine induction after infection. Monocyte-derived and bronchoalveolar macrophages from 10 adult horses and from 10 foals (sampled at 1-3 days, 2 weeks, 1 month, 3 months, and 5 months of age) were infected ex vivo with virulent R. equi. Intracellular R. equi were quantified and mRNA expression of IL-1β, IL-4, IL-6, IL-8, IL-10, IL-12 p40, IL-18, IFN-γ, and TNF-α was measured. Intracellular replication of R. equi was significantly (P<0.001) greater in bronchoalveolar than in monocyte-derived macrophages, regardless of age. Regardless of the macrophage lineage, replication of R. equi was significantly (P=0.002) higher in 3-month-old foals than in 3-day old foals, 2-week-old foals, 1-month-old foals, and adult horses. Expression of IL-4 mRNA was significantly higher in monocyte-derived macrophages whereas expression of IL-6, IL-18, and TNF-α was significantly higher in bronchoalveolar macrophages. Induction of IL-1β, IL-10, IL-12 p40, and IL-8 mRNA in bronchoalveolar macrophages of 1-3-day old foals was significantly higher than in older foals or adult horses. Preferential intracellular survival of R. equi in bronchoalveolar macrophages of juvenile horses may play a role in the pulmonary tropism of the pathogen and in the window of age susceptibility to infection.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cytokines; Foal; Macrophage; Pneumonia; Rhodococcus equi

Mesh:

Substances:

Year:  2014        PMID: 24736188     DOI: 10.1016/j.vetimm.2014.03.010

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  7 in total

1.  Effect of Macrolide and Rifampin Resistance on Fitness of Rhodococcus equi during Intramacrophage Replication and In Vivo.

Authors:  Jennifer M Willingham-Lane; Londa J Berghaus; Roy D Berghaus; Kelsey A Hart; Steeve Giguère
Journal:  Infect Immun       Date:  2019-09-19       Impact factor: 3.441

2.  Effects of Recombinant Toxoplasma gondii Citrate Synthase I on the Cellular Functions of Murine Macrophages In vitro.

Authors:  Xinchao Liu; Qunshan Ma; Xiaoni Sun; Mingmin Lu; Muhammad Ehsan; Muhammad Waqqas Hasan; Lixin Xu; RuoFeng Yan; XiaoKai Song; XiangRui Li
Journal:  Front Microbiol       Date:  2017-07-21       Impact factor: 5.640

3.  Strain-to-strain variation of Rhodococcus equi growth and biofilm formation in vitro.

Authors:  Adina R Bujold; Nicholas R Lani; Macarena G Sanz
Journal:  BMC Res Notes       Date:  2019-08-19

4.  Host-directed therapy in foals can enhance functional innate immunity and reduce severity of Rhodococcus equi pneumonia.

Authors:  Angela I Bordin; Noah D Cohen; Steve Giguère; Jocelyne M Bray; Londa J Berghaus; Brenton Scott; Rena Johnson; Magnus Hook
Journal:  Sci Rep       Date:  2021-01-28       Impact factor: 4.379

5.  The type of anticoagulant used for plasma collection affects in vitro Rhodococcus equi assays.

Authors:  Alejandra A Rivolta; Dana C Pittman; Amanda J Kappes; Robert K Stancil; Clark Kogan; Macarena G Sanz
Journal:  BMC Res Notes       Date:  2022-02-14

6.  An Adenoviral Vector Based Vaccine for Rhodococcus equi.

Authors:  Carla Giles; Olasumbo Ndi; Mary D Barton; Thiru Vanniasinkam
Journal:  PLoS One       Date:  2016-03-23       Impact factor: 3.240

7.  Opsonization but not pretreatment of equine macrophages with hyperimmune plasma nonspecifically enhances phagocytosis and intracellular killing of Rhodococcus equi.

Authors:  Aja B Harvey; Angela I Bordin; Joana N Rocha; Jocelyn M Bray; Noah D Cohen
Journal:  J Vet Intern Med       Date:  2020-12-16       Impact factor: 3.175

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.